Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety and Efficacy of Biphasic Human Insulin Compared to EX1000 in Type 2 Diabetes

This study has been completed.
Information provided by (Responsible Party):
Novo Nordisk A/S Identifier:
First received: June 16, 2008
Last updated: April 13, 2015
Last verified: April 2015
This trial is conducted in Asia and Africa. This trial aims for a comparison of blood glucose control of biphasic human insulin 100 IU/mL and EX1000.

Condition Intervention Phase
Diabetes Mellitus, Type 2
Drug: EX1000
Drug: biphasic human insulin
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Assessment of Safety and Efficacy of Biphasic Human Insulin IU 100 to EX1000 on Glycaemic Control in Subjects With Type 2 Diabetes

Resource links provided by NLM:

Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • HbA1c [ Time Frame: after 8 weeks of treatment ]

Secondary Outcome Measures:
  • HbA1c [ Time Frame: For the duration of the trial ]
  • Fructosamine [ Time Frame: For the duration of the trial ]
  • FPG [ Time Frame: For the duration of the trial ]
  • 4-point SMPG profiles [ Time Frame: For the duration of the trial ]
  • Incidence of hypoglycaemic episodes [ Time Frame: For the duration of the trial ]
  • Frequency and severity of adverse events (including injection site reactions) [ Time Frame: For the duration of the trial ]
  • Laboratory safety parameters (haematology, biochemistry and lipids) [ Time Frame: For the duration of the trial ]
  • Physical examination and vital signs [ Time Frame: For the duration of the trial ]
  • Total daily insulin dosages [ Time Frame: For the duration of the trial ]

Enrollment: 397
Study Start Date: June 2008
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: EX1000
Treat-to-target titration scheme, s.c. injection
Active Comparator: B Drug: biphasic human insulin
Treat-to-target titration scheme, s.c. injection


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 2 diabetes for at least 12 months
  • Current biphasic human insulin (BHI) for at least 3 months - as monotherapy or as the only insulin in combination with OADs
  • Body Mass Index (BMI) less than or equal to 40.0 kg/m2
  • HbA1c less than or equal to 9.5%
  • FPG (SMPG) less than or equal to 12 mmol/L

Exclusion Criteria:

  • Treatment with more than 1IU/kg insulin daily
  • Treatment with Glucagon-like peptide 1 mimetics or dipeptityl peptidase IV inhibitors
  • Known hypoglycaemia unawareness or recurrent major hypoglycaemia, as judged by the Investigator
  • Known or suspected allergy to trial products or related products
  • Receipt of any investigational drug within one month prior to this trial
  • Any other condition that the Investigator feels would interfere with trial participation or evaluation of results, e.g. shiftworkers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00698802

Vijayawada, India, 520002
South Africa
Johannesburg, Gauteng, South Africa, 2193
United Arab Emirates
Abu Dhabi, United Arab Emirates, 51900
Sponsors and Collaborators
Novo Nordisk A/S
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
Responsible Party: Novo Nordisk A/S Identifier: NCT00698802     History of Changes
Other Study ID Numbers: EX1000-1919
Study First Received: June 16, 2008
Last Updated: April 13, 2015

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin, Globin Zinc
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on April 28, 2017